New
HealthMore in Health→
Semaglutide's Kidney Protection Tied to Lower Vascular Resistance and Less Fibrosis
Key Takeaways
- A 52-week randomized, placebo-controlled trial in Nature Medicine tested subcutaneous semaglutide 1 mg weekly against placebo in 106 adults with type 2 diabetes and chronic kidney disease (25 women, 81 men).
- Multiparametric kidney MRI plus biopsy was performed in 33 participants, with single-nucleus transcriptomics in 22 and spatial transcriptomics in 13, using paired before- and after-treatment samples.
- Coprimary MRI outcomes — oxygenation by R2*, global perfusion, and inflammation by T1 mapping — were not significantly altered by semaglutide.
- Secondary outcomes showed a significantly reduced renal artery resistive index and stabilization of the apparent diffusion coefficient, indicating prevention of fibrosis progression.
DE
DT Editorial Team··via nature.com